Neuroone Medical Technologies (NMTC) executive compensation, 2026 proxy

Dave Rosa, Chief Executive Officer and President, was paid $1.2M in 2025, down 42% from $2M the year before.

Filed
March 9, 2026
Annual meeting
April 3, 2026
Pay year
2025
Named executives
3
CEO total pay
$1.2M-42% vs prior year
CEO Base Salary
$535,428Fiscal year 2025 base salary
CEO Target Bonus
50%Percentage of annual base salary
Bonus Payout Percentage
94%Achieved corporate performance targets
CEO Option Awards
$367,357Aggregate grant date fair value
CEO Option Grant
750,000Stock options granted in April 2025

How Rosa was paid

$1.2M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary46%Option awards32%Non-equity incentive22%

Named executive officers

ExecutiveTotal
Dave RosaChief Executive Officer and President$1,154,436
Christoper VolkerChief Operating Officer$687,373
Ron McClurgChief Financial Officer$523,822

What changed and why

  • $1.2MChief Executive Officer total compensation decreased to $1,154,436 in fiscal year 2025 compared to $1,995,745 in fiscal year 2024.
  • 2.6%Named executive officers received a 2.6% increase for cost of living adjustments in fiscal year 2025.
  • 94%Performance targets for the fiscal year 2025 bonus were met at 94% achievement level.
  • Option awards for named executive officers in fiscal year 2025 included 750,000 shares granted to the CEO.
  • Named executive officers received no stock awards in fiscal year 2025 compared to previous restricted stock grants.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.